Evidence map›Paper›PMID 40088370›Full record

ReviewInflammopharmacology2025

Interplay between PI3k/AKT signaling and caspase pathway in Alzheimer disease: mechanism and therapeutic implications.

Vandana Bhatia, Vir Vikram, Anjali Chandel, Aditya Rattan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vandana BhatiaDepartment of Pharmacology, CT University Ludhiana, Ludhiana, Punjab, 142024, India. Vandana.bhatia40@gmail.com.ORCID http://orcid.org/0000-0002-1614-7192
Vir VikramDepartment of Pharmacology, CT University Ludhiana, Ludhiana, Punjab, 142024, India.
Anjali ChandelDepartment of Pharmacology, Laureate Institute of Pharmacy Kathog, Kangra, 177101, India.
Aditya RattanDepartment of Pharmacology, Laureate Institute of Pharmacy Kathog, Kangra, 177101, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease, a neurodegenerative disorder, is characterized by cognitive impairment, neuronal loss, and synaptic dysfunction. The interplay between the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway and the caspase-mediated apoptotic cascade plays a pivotal role in its progression. The signaling pathway responsible for neuronal survival also regulates synaptic plasticity and resistance to oxidative stress, whereas caspase activation accelerates neurodegeneration by triggering cell death and inflammation. Dysregulation of these pathways leads to amyloid-beta (Aβ) accumulation, tau hyperphosphorylation, and mitochondrial dysfunction, creating a negative feedback loop and accelerating disease progression. Emerging treatment methods that target PI3K/AKT activation and caspase inhibition have showed promise in preclinical models, preventing neuronal apoptosis while retaining cognitive function. This review investigates the molecular processes driving PI3K/AKT and caspase crosstalk, their significance in Alzheimer's disease, and prospective therapeutic strategies aiming at regulating these pathways to improve disease outcomes.

Indexed as

Alzheimer DiseaseCaspasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAmyloid beta-PeptidesAnimalsApoptosisHumansSignal TransductionAmyloid beta-PeptidesCaspasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAlzheimer’s diseaseApoptosis neurodegenerationCaspase pathwayNeuroprotectionPI3K/AKT signaling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.